139 related articles for article (PubMed ID: 33964839)
1. HISTOPATHOLOGICAL, PROLIFERATIVE, APOPTOTIC AND HORMONAL CHARACTERISTICS OF VARIOUS TYPES OF LEIOMYOMAS.
Kiknadze T; Tevdorashvili G; Muzashvili T; Gachechiladze M; Burkadze G
Georgian Med News; 2021 Mar; (312):119-125. PubMed ID: 33964839
[TBL] [Abstract][Full Text] [Related]
2. PHENOTYPIC CHARACTERISTICS OF RELAPSED LEIOMYOMA AND SMOOTH MUSCLE TUMORS OF UNCERTAIN MALIGNANCY POTENTIAL IN REPRODUCTIVE WOMEN.
Kiknadze T; Tevdorashvili G; Muzashvili T; Gachechiladze M; Burkadze G
Georgian Med News; 2021 Jan; (310):150-156. PubMed ID: 33658424
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
4. [Histological diagnosis and clinical features in borderline smooth muscle tumors of the uterus].
Shi YF; Xie X; Zhao CL
Zhonghua Fu Chan Ke Za Zhi; 1994 Apr; 29(4):201-4, 251. PubMed ID: 8082439
[TBL] [Abstract][Full Text] [Related]
5. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
6. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis in the diagnosis of uterine myometrial smooth muscle tumors.
Stănescu AD; Nistor E; Sajin M; Stepan AE
Rom J Morphol Embryol; 2014; 55(3 Suppl):1129-36. PubMed ID: 25607395
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
[TBL] [Abstract][Full Text] [Related]
9. Inguinal smooth muscle tumors in women-a dichotomous group consisting of Müllerian-type leiomyomas and soft tissue leiomyosarcomas: an analysis of 55 cases.
Patil DT; Laskin WB; Fetsch JF; Miettinen M
Am J Surg Pathol; 2011 Mar; 35(3):315-24. PubMed ID: 21297441
[TBL] [Abstract][Full Text] [Related]
10. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
Mittal K; Demopoulos RI
Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
[TBL] [Abstract][Full Text] [Related]
11. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
12. Expression of the O-linked N-acetylglucosamine containing epitope H in normal myometrium and uterine smooth muscle cell tumors.
Sgantzos MN; Galani V; Arvanitis LD; Charchanti A; Psathas P; Nakou M; Havaki S; Kallioras V; Marinos E; Vamvakopoulos NC; Kittas C
Pathol Res Pract; 2007; 203(1):31-7. PubMed ID: 17129677
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
Shanes ED; Friedman LA; Mills AM
Am J Surg Pathol; 2019 Jun; 43(6):792-801. PubMed ID: 31009388
[TBL] [Abstract][Full Text] [Related]
14. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
Schwetye KE; Pfeifer JD; Duncavage EJ
Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
[TBL] [Abstract][Full Text] [Related]
15. [Mesenchymal uterine tumors. Leiomyomas].
Lax S
Pathologe; 2009 Jul; 30(4):274-83. PubMed ID: 19495761
[TBL] [Abstract][Full Text] [Related]
16. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
17. Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy.
Ip PP; Tse KY; Tam KF
Adv Anat Pathol; 2010 Mar; 17(2):91-112. PubMed ID: 20179432
[TBL] [Abstract][Full Text] [Related]
18. Uterine smooth muscle tumors of uncertain malignant potential and atypical leiomyoma: a morphological study of these grey zones with clinical correlation.
Deodhar KK; Goyal P; Rekhi B; Menon S; Maheshwari A; Kerkar R; Tongaonkar HB
Indian J Pathol Microbiol; 2011; 54(4):706-11. PubMed ID: 22234095
[TBL] [Abstract][Full Text] [Related]
19. Symplastic leiomyomas of the scrotum: a comparative study to usual leiomyomas and leiomyosarcomas.
Matoso A; Chen S; Plaza JA; Osunkoya AO; Epstein JI
Am J Surg Pathol; 2014 Oct; 38(10):1410-7. PubMed ID: 24832157
[TBL] [Abstract][Full Text] [Related]
20. Variant type of leiomyomas: 13 years of experience in a single institution.
Bacanakgil BH; Ilhan G; Kaban I
Ginekol Pol; 2022; 93(6):444-449. PubMed ID: 34155617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]